|
|
|
Volumn 32, Issue 4, 1995, Pages 304-312
|
|
Chelation therapy in β-thalassemia: The benefits and limitations of desferrioxamine
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ASCORBIC ACID;
DEFEROXAMINE;
DEFEROXAMINE MESYLATE;
FERRITIN;
IRON;
BETA THALASSEMIA;
BLOOD TRANSFUSION;
CATARACT;
DRUG EFFICACY;
DRUG SAFETY;
FERRITIN BLOOD LEVEL;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
IRON CHELATION;
IRON OVERLOAD;
NEUROPATHY;
PRIORITY JOURNAL;
REVIEW;
SPLENECTOMY;
TREATMENT OUTCOME;
ADOLESCENT;
ADULT;
BLOOD TRANSFUSION;
CHELATING AGENTS;
CHELATION THERAPY;
CHILD;
DEFEROXAMINE;
GROWTH DISORDERS;
HEARING LOSS;
HEART DISEASES;
HEMOCHROMATOSIS;
HEMOSIDEROSIS;
HUMAN;
IRON;
KIDNEY DISEASES;
LUNG DISEASES;
SUPPORT, NON-U.S. GOV'T;
SUPPORT, U.S. GOV'T, P.H.S.;
THALASSEMIA;
VISION DISORDERS;
|
|
EID: 0028861997
PISSN: 00371963
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (75)
|
|
References (0)
|
